Private Advisory Group LLC Grows Holdings in Novo Nordisk A/S $NVO

Private Advisory Group LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 25.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 233,014 shares of the company’s stock after buying an additional 47,198 shares during the quarter. Private Advisory Group LLC’s holdings in Novo Nordisk A/S were worth $11,856,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in NVO. True Wealth Design LLC raised its holdings in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after acquiring an additional 300 shares in the last quarter. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S during the 3rd quarter worth $25,000. Strengthening Families & Communities LLC bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth about $30,000. Allianz SE increased its position in shares of Novo Nordisk A/S by 70.0% in the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after purchasing an additional 238 shares during the last quarter. Finally, Financial Life Planners acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $33,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.1%

NYSE:NVO opened at $36.01 on Monday. The firm has a market capitalization of $160.78 billion, a P/E ratio of 10.38, a P/E/G ratio of 8.52 and a beta of 0.73. The business has a 50 day simple moving average of $45.92 and a 200 day simple moving average of $50.42. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. Novo Nordisk A/S has a 12-month low of $35.85 and a 12-month high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. This represents a dividend yield of 708.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 52.74%.

Analyst Ratings Changes

Several equities analysts have recently commented on NVO shares. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research report on Tuesday, March 10th. Finally, Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Four investment analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves Awiqli (insulin icodec‑abae), the first once‑weekly basal insulin for adults with type 2 diabetes — expands treatment choices, may improve adherence vs daily basal insulin and supports a U.S. launch in the second half of 2026. US FDA approves Novo’s insulin injection for type 2 diabetes
• Positive Sentiment: Corporate governance/market strategy bolstered by appointment of Mars CEO Poul Weihrauch as a board observer — intended to strengthen Novo’s positioning and commercial insights in the competitive U.S. obesity market. Novo Nordisk appoints Mars CEO as board observer
• Neutral Sentiment: Filed updated Articles of Association and capital‑increase mandate — routine corporate housekeeping that can enable share issuance or compensation plans but has no immediate earnings impact. Articles of Association for Novo Nordisk A/S 2026
• Neutral Sentiment: Mixed analyst coverage: Wolfe Research started coverage with a “peer perform” rating and some brokers give neutral takes on the pipeline — underscores divergent views on growth sustainability vs valuation.
• Neutral Sentiment: Pipeline commentary: promising signals for next‑generation candidates (e.g., UBT251 triple‑agonist) but analysts flag that new oral drug trends and incremental data so far are not yet transformative. GLP‑1 pipeline shows promise but oral drug trends give analysts pause
• Negative Sentiment: Bernstein initiated coverage with an Underperform rating and a low price target, warning the company’s earnings downgrade cycle may not be over — a clear near‑term headwind for sentiment and the stock. Bernstein initiates coverage with Underperform
• Negative Sentiment: Recent headlines and analyst notes have coincided with share weakness and short‑term selling — valuation concerns (forward P/E in the low double digits vs peers) and profit‑taking after prior rallies are weighting the stock. Stock slides as market rises

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.